Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
MWN-AI** Summary
Propanc Biopharma, Inc. (Nasdaq: PPCB), a biopharmaceutical company devoted to developing innovative treatments for chronic diseases, has filed a new provisional patent application with IP Australia for methods to produce trypsinogen and chymotrypsinogen. This patent outlines an optimized expression system designed to create a fully synthetic recombinant version of the company’s flagship product, PRP, which aims to serve as a long-term therapy for the treatment and prevention of metastatic cancer stemming from solid tumors.
The global metastatic cancer market is on track to reach an estimated $111 billion by 2027, highlighting the significance of Propanc's advancement in therapeutic approaches. The synthetic proenzymes produced via an in vivo system, such as yeast cells, boast extended shelf lives without refrigeration, thereby facilitating global distribution, especially in regions with limited refrigeration capabilities. This development could notably benefit healthcare systems by providing consistent, large-scale production of trypsinogen and chymotrypsinogen without reliance on animal sources, thereby reducing variability among lots.
Mr. James Nathanielsz, CEO of Propanc, emphasized that this provisional patent marks the third application filed in just two months and contributes significantly to the company's intellectual property portfolio, supporting their strategy to expand into international markets. Propanc aims to establish a platform technology as a groundbreaking therapeutic approach to combating metastatic cancer, while also seeking to explore additional therapeutic areas with substantial unmet medical needs.
Overall, the advancements underscore Propanc's commitment to addressing cancer recurrence and metastasis through novel, less harmful methods, ultimately working towards a solid and sustainable future for the company and its shareholders. More details can be found at www.propanc.com.
MWN-AI** Analysis
Propanc Biopharma, Inc. (Nasdaq: PPCB) has made notable strides in its innovation pipeline with the recent filing of a provisional patent application for the production of trypsinogen and chymotrypsinogen. This initiative indicates the company’s strong commitment to developing novel cancer therapies, potentially positioning it favorably within a projected $111 billion metastatic cancer market by 2027. The development of Rec-PRP (recombinant proenzyme therapy), which can be produced sustainably without refrigeration, highlights Propanc's dedication to addressing logistical challenges in global healthcare distribution, particularly in regions with limited access to cold storage.
From an investment standpoint, this patent filing enhances Propanc's intellectual property (IP) portfolio, which is critical in building long-term shareholder value. IP protection can lead to a competitive edge and potentially attract strategic partnerships or licensing opportunities, vital for biopharma companies in the capital-intensive drug development landscape.
Additionally, the management’s focus on expanding research into other therapeutic areas where unmet medical needs exist may further bolster the company’s market positioning. The proactive approach to securing and expanding its IP reflects a well-thought-out strategy that could mitigate risks associated with future market shifts and competition.
However, potential investors should remain cognizant of inherent risks tied to biotechnology investments, including regulatory hurdles and the unpredictability of clinical trial outcomes. Propanc’s successful navigation of these challenges will be crucial in realizing its ambitious vision.
In summary, while Propanc has laid a strong foundation for future growth and innovation, investors should monitor the company’s progress through regulatory milestones and clinical trial advancements, balancing potential gains against the high-risk nature of the biopharmaceutical development process. Overall, PPCB warrants attention for those interested in the evolving landscape of cancer therapeutics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MELBOURNE, , Jan. 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that a new provisional patent application has been filed for methods of producing trypinsogen and chymotrypsinogen with IP Australia. The patent application describes an optimized expression system to produce a world-first fully synthetic recombinant version of PRP, a long-term therapy for the treatment and prevention of metastatic cancer from solid tumors. According to Emergen Research, the global metastatic cancer market is projected to be worth $111 Billion by 2027.
A fully synthetic version of trypsinogen and chymotrypsinogen, called Rec-PRP, could have additional benefits to a global healthcare system that further capitalizes on a new therapeutic approach to treating cancer. For example, both proenzymes are synthesized by an in vivo (living organism) expression system, such as yeast cells, to produce proteins that could be maintained for long periods of time without suffering degradation in the absence of refrigeration. This is useful for a longer self-life as well as global distribution, particularly in warmer climates and developing regions where refrigeration is not available. Further, the program could produce large quantities of trypsinogen and chymotrypsinogen for commercial use that exhibits minimal variation between lots and without sourcing from animals. Therefore, management believes a fully synthetic recombinant version of PRP would have tremendous implications from a regulatory perspective, but also a practical, commercial benefit for global distribution.
“This provisional patent application is the third one filed over the past two months and will enhance our IP portfolio significantly as we enter national phase in countries worldwide for each of these patent applications,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “We continue to execute our strategic plan building a platform technology that could be a world-first therapeutic approach to metastatic cancer from solid tumors, but without severe or serious side effects associated with standard treatments. Further, we are expanding our research into other therapeutic indications where there is a significant unmet medical need. We are building a strong and stable future for our Company and shareholders over the long term.”
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.
More information: www.propanc.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com
FAQ**
How does Propanc Biopharma Inc (PPCB) plan to ensure that their fully synthetic recombinant version of PRP can effectively compete in the projected $1Billion metastatic cancer market by 2027?
What specific advantages does Propanc Biopharma Inc (PPCB) expect from their new provisional patent related to trypinsogen and chymotrypsinogen in terms of global distribution and shelf-life?
Can you elaborate on how Propanc Biopharma Inc (PPCB)'s technology for synthesizing proenzymes aims to address the regulatory challenges typically associated with cancer treatment?
In what ways is Propanc Biopharma Inc (PPCB) diversifying its research efforts to target other unmet medical needs in conjunction with their primary focus on metastatic cancer therapies?
**MWN-AI FAQ is based on asking OpenAI questions about Propanc Biopharma Inc (OTC: PPCB).
NASDAQ: PPCB
PPCB Trading
61.54% G/L:
$2.87 Last:
496,164 Volume:
$4 Open:
